I think we’ll see a modest pop when the second portion of the BLA is submitted and perhaps a more substantial ramp up when the application is complete (and it becomes clear that we really are on track for revenue). I’m not sure if that alone will be enough to get us where we need to be to uplist, but if the next update on our recent cancer patients shows anything like what we saw with the first two, then we could run.